Related Experiment Video

Updated: Jul 6, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K

Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC

Sukanya Panja1, Mihai Ioan Truica2, Christina Y Yu1

  • 1Department of Health Informatics, Rutgers School of Health Professions, Newark, NJ, 07107, USA.

Nature Communications
|January 8, 2024
PubMed

Insights

Enzalutamide resistance in prostate cancer is common. This study identifies NME2-MYC activity as a predictor of resistance and a therapeutic target for improved treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Enzalutamide is a key treatment for castration-resistant prostate cancer (CRPC).
  • Patient response to Enzalutamide is highly variable, necessitating research into resistance mechanisms.
  • Identifying biomarkers and therapeutic targets is crucial for managing CRPC effectively.

Purpose of the Study:

  • To investigate the role of MYC in Enzalutamide resistance in CRPC.
  • To construct a CRPC-specific regulatory network to identify key molecular players.
  • To discover novel therapeutic strategies for Enzalutamide-resistant prostate cancer.

Main Methods:

  • Genome-wide systems investigation to build a mechanism-centric regulatory network.
  • Network mining using Enzalutamide response signatures.
  • Experimental validation of identified targets in Enzalutamide-resistant models.

Main Results:

  • MYC was identified as a de novo marker of Enzalutamide resistance.
  • NME2 was identified as an upstream regulatory partner of MYC in CRPC.
  • Increased NME2-MYC activity predicts Enzalutamide resistance independently of other factors.
  • Targeting MYC and NME2 demonstrated therapeutic benefits in Enzalutamide-resistant conditions.

Conclusions:

  • NME2-MYC activity serves as a predictive biomarker for Enzalutamide resistance in CRPC patients.
  • Targeting the NME2-MYC axis offers a promising therapeutic strategy for Enzalutamide-resistant prostate cancer.
  • This research provides a foundation for developing salvage therapies for patients with advanced prostate cancer.

More Related Videos

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

12.8K
High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

9.5K

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
6.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.1K